MARKET WIREReuters • 46m ago
Iranians have left Doha talks, draft proposal for US deal being circulated, official says - ReutersIranians have left Doha talks, draft proposal for US deal being circulated, official says Reuters
Why ARMP Stock slipped -1.22% Today — RQD Quant Desk Flash
$3.25 -1.22% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $3.24
Armata Pharmaceuticals Inc. (ARMP) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • SELL / AVOID
Cap $120.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ARMP Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ARMP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Armata Pharmaceuticals Inc. (NYSE: ARMP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $3.25 (-1.22% 1D, market cap $120.8M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ARMP ranks #462 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ARMP compare to AVXL and OTLK in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ARMP carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AVXL (Anavex Life Sciences Corp.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $120.5M) and OTLK (Outlook Therapeutics Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $120.1M). Among the 5-stock peer group, ARMP leads on earnings multiple (N/A) while ARMP leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ARMP?
▼
Per ARMP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000921114), Armata Pharmaceuticals Inc. generated $0 in revenue, -$173.8M in net income, and -$26.3M in free cash flow against $76.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $3.24 (-0.41%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-6.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ARMP)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (43/100 Composite)
🔍 WHY ARMP SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (28% of score)
FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 43.8 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (23% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$3.63-7.2% Next Q
51
Q2 (-2Q)Grade D$3.37+8% Next Q
48
Q3 (-1Q)Grade D$3.64-10.7% Next Q
46
CurrentGrade D-$3.25-6.7% Hist 90D α
43
Trajectory: C- (51) → D- (43)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ARMP Turnaround Squeeze
While ARMP currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.18) and Max Pain ($3.41) forces dealer call-delta covering toward $15.73.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ARMP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ARMP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ARMP Stock slipped -1.22% Today — RQD Quant Desk Flash
Armata Pharmaceuticals Inc. (ARMP) slipped -1.22% to $3.25, trading at 4% of its 52-week range ($2.75 – $14.98). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 4% of its 52-week range ($2.75 – $14.98) with RSI-14 at 43.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $3.25 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live ARMP Headlines & Catalysts
MARKET WIREReuters • 2h ago
COMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag - ReutersCOMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag Reuters
MARKET WIREReuters • 3h ago
Saudi civil defence sounds all-clear after alerts in southern cities - ReutersSaudi civil defence sounds all-clear after alerts in southern cities Reuters
MARKET WIREReuters • 4h ago
World's energy supply buffers have been eroded, ADNOC CEO says - ReutersWorld's energy supply buffers have been eroded, ADNOC CEO says Reuters
MARKET WIREReuters • 6h ago
Gold rises on softer oil; markets parse Fed signals - ReutersGold rises on softer oil; markets parse Fed signals Reuters
MARKET WIREReuters • 6h ago
China's Xi says Middle East should not become battleground for great power rivalry - ReutersChina's Xi says Middle East should not become battleground for great power rivalry Reuters
MARKET WIREReuters • 8h ago
Reliance earnings, lower oil prices power India's Sensex to near two-month high - ReutersReliance earnings, lower oil prices power India's Sensex to near two-month high Reuters
MARKET WIREReuters • 10h ago
Dollar pulls back ahead of US midterms; bitcoin stabilises after crypto heist - ReutersDollar pulls back ahead of US midterms; bitcoin stabilises after crypto heist Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ARMP)
- ✓Walkthrough of ARMP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ARMP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -67.43%📐 HORIZONTAL RANGE
2026-10-30O $3.39H $3.44L $3.20C $3.25VOL 46.7K
RES: $7.72SUP: $2.42SMA50: $4.18SMA200: $7.01
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ARMP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ARMP today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ARMP. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ARMP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ARMP)
Health Care Rank #462 of 1016
⚔️ AVXL vs ARMP Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ARMP vs. AVXL, OTLK, HUMA, MOLN)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Armata Pharmaceuticals Inc. (ARMP) ranks #462 by composite RQD confidence (43/100, grade D-) and #633 by equity capitalization ($120.8M). Within this direct 5-issuer industry benchmark cohort, ARMP leads on earnings valuation at N/A trailing P/E, while ARMP leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. MOLN currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with ARMP at 43/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ARMP
ACTIVE
Armata Pharmaceuticals Inc. | D- | 43/100 | — | — | -35.0% | -1.22% | $120.8M | Benchmark Subject |
| AVXL Anavex Life Sciences Corp. | E | 32/100 | — | — | -35.0% | 0.00% | $120.5M | /avxl-vs-armp → |
| OTLK Outlook Therapeutics Inc. | D- | 38/100 | — | 4.0% | -35.0% | -9.43% | $120.1M | /otlk-vs-armp → |
| HUMA Humacyte Inc. | E | 31/100 | — | -30.0% | -35.0% | -0.06% | $130.5M | /huma-vs-armp → |
| MOLN Molecular Partners AG | D | 50/100 | — | — | — | -4.88% | $132.4M | /moln-vs-armp → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000921114In its most recent audited fiscal period (FY2025, filed 2025-12-31), Armata Pharmaceuticals Inc. (ARMP) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$173.8M, operating cash flow of -$25.8M, and free cash flow of -$26.3M (+33.3% YoY). On the balance sheet, ARMP closed FY2025 with $76.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$173.8M | -$25.8M | -$26.3M | $76.9M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$18.9M | -$37.6M | -$39.4M | $86.4M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$69.0M | -$47.4M | -$47.4M | — | — |
3. ARMP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ARMP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Armata Pharmaceuticals Inc. (NYSE: ARMP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $3.25 (-1.22% 1D, market cap $120.8M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ARMP ranks #462 in composite RQD confidence.
How does ARMP compare to AVXL and OTLK in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ARMP carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AVXL (Anavex Life Sciences Corp.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $120.5M) and OTLK (Outlook Therapeutics Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $120.1M). Among the 5-stock peer group, ARMP leads on earnings multiple (N/A) while ARMP leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ARMP?
Per ARMP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000921114), Armata Pharmaceuticals Inc. generated $0 in revenue, -$173.8M in net income, and -$26.3M in free cash flow against $76.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ARMP trading relative to its 50-day, 200-day, and 52-week technical levels?
ARMP last traded at $3.25 (-1.22% on volume of 102,957 shares), positioning the stock -22.25% below its 50-day simple moving average ($4.18) and -53.64% below its 200-day simple moving average ($7.01). Across its 52-week range of $2.75 to $14.98, ARMP sits at the 4.1% percentile with a 14-day RSI of 43.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.84 to $3.66).
ARMP Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ARMP stock moving today?
Why ARMP Stock slipped -1.22% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.